Shots:
- The US FDA has approved Blenrep + BorDex for the treatment of r/r MM in adults who have received ≥1 prior therapy, incl. a proteasome inhibitor & an immunomodulatory agent. NDA under NMPA’s priority review
- Approval was based on P-III (DREAMM-7) trial assessing Blenrep (2.5mg/kg, IV, Q3W) in combination with BorDex for 8 cycles, then as a single agent vs Darzalex + BorDex in 494 pts with r/r MM
- DREAMM-7 showed a 51% reduction in death risk (mPFS: 31.3 vs 10.4mos.) in 3L+ pts; follow-up OS data from DREAMM-7 & 8, as well as data from P-III (DREAMM-10) trial in newly diagnosed, transplant-ineligible pts are expected in early 2028, with US site expansion for DREAMM-10
Ref: GSK | Image: GSK | Press Release
Related News:- GSK’s Shingrix PFS Presentation Receives the CHMP’s Positive Opinion
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
